BIOMAT Database Logo BIOMAT Database Logo

Highly selective mu opioid antagonist peptides block spinal mu opioid inhibition of gastrointestinal transit. 1988

E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Department of Pharmacology, University of Arizona, Tucson 85724.

UI MeSH Term Description Entries
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005772 Gastrointestinal Transit Passage of food (sometimes in the form of a test meal) through the gastrointestinal tract as measured in minutes or hours. The rate of passage through the intestine is an indicator of small bowel function. GI Transit,GI Transits,Gastrointestinal Transits,Transit, GI,Transit, Gastrointestinal,Transits, GI,Transits, Gastrointestinal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D017450 Receptors, Opioid, mu A class of opioid receptors recognized by its pharmacological profile. Mu opioid receptors bind, in decreasing order of affinity, endorphins, dynorphins, met-enkephalin, and leu-enkephalin. They have also been shown to be molecular receptors for morphine. Morphine Receptors,Opioid Receptors, mu,Receptors, Morphine,Receptors, mu,Receptors, mu Opioid,mu Receptors,Morphine Receptor,mu Opioid Receptor,mu Receptor,Opioid Receptor, mu,Receptor, Morphine,Receptor, mu,Receptor, mu Opioid,mu Opioid Receptors
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit.
May 1998, Brain research. Molecular brain research,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats.
August 2006, Brain research,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Role of peripheral mu, delta and kappa opioid receptors in opioid-induced inhibition of gastrointestinal transit in rats.
July 1990, The Journal of pharmacology and experimental therapeutics,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Six highly active mu-selective opioid peptides identified from two synthetic combinatorial libraries.
January 1995, Peptide research,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Alvimopan, a selective peripherally acting mu-opioid antagonist.
April 2005, Neurogastroenterology and motility,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Synthesis of highly mu and delta opioid receptor selective peptides containing a photoaffinity group.
March 1989, Journal of medicinal chemistry,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Sympathoadrenal, cardiovascular and blood gas responses to highly selective mu and delta opioid peptides.
December 1989, The Journal of pharmacology and experimental therapeutics,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides.
October 1989, Digestive diseases and sciences,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Structural characteristics of two highly selective opioid peptides.
January 1989, BioEssays : news and reviews in molecular, cellular and developmental biology,
E A Ayres, and R Villar, and T H Kramer, and W Kazmierski, and V J Hruby, and T F Burks
Chronic opioid antagonist treatment increases mu and delta receptor mediated spinal opioid analgesia.
April 1989, Brain research,
Copied contents to your clipboard!